LP-6 (TFA)

• Description :

  LP-6 TFA is a Drug-Linker Conjugate for ADC, and can be used for synthesis of ADCs. LP-6 TFA consists of an Eg5 inhibitor and a linker[1].

• CAS Number :

  [1629741-09-8]

• UNSPSC :

  12352005

• Target :

  Drug-Linker Conjugates for ADC; Kinesin

• Related Pathways :

  Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton

• Field of Research :

  Cancer

• Purity :

  99.61

• Smiles :

  F[C@@H](CNC1)[C@@H]1CN(C([C@@H](O)C)=O)[C@@H](C2=NC(C3=C(C=CC(F)=C3)F)=CN2CC4=CC=CC=C4)C(C)(C)CC(NCCN5C(C=CC5=O)=O)=O.OC(C(F)(F)F)=O.[x]

• Molecular Formula :

  C36H41F3N6O5·xC2HF3O2

• Molecular Weight :

  694.74 (free base)

• References & Citations :

  [1]Karpov AS, et al. Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization. ACS Med Chem Lett. 2019 Dec 3;10 (12) :1674-1679.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, sealed storage, away from moisture and light)

• Scientific Category :

  ADC Related

• Clinical Information :

  No Development Reported

• Isoform :

  Kinesin-5/Eg5/KSP